Premium
Matrix‐Metalloprotease Resistant Mucin‐16 (MUC16) Peptide Mutants Represent a Worse Lung Adenocarcinoma Outcome
Author(s) -
Patel Jay S.,
Callahan Blake M.,
Chobrutskiy Boris I.,
Blanck George
Publication year - 2019
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201800155
Subject(s) - mutant , proteases , mucin , adenocarcinoma , protease , biology , peptide , cancer research , microbiology and biotechnology , chemistry , gene , biochemistry , cancer , enzyme , genetics
Purpose The relationship of lung adenocarcinoma (LUAD)–specific proteases and the mutant profile of cytoskeletal and extracellular matrix proteins (CECMPs) are examined. Experimental design Mutant CECMPs are assessed with an automated application of a protease binding, amino acid–based, scoring database. Results MUC16 (Human Genome Organization symbol for mucin‐16 gene) mutants in particular are, more often than not, resistant to matrix‐metalloproteases (MMPs) commonly secreted by LUAD cells, and LUAD cases representing the MUC16, MMP resistant mutants have a worse outcome. Similar results are obtained for MUC16 mutants resistant to cathepsins, also commonly secreted by LUAD cells. Analyses also show that MUC16, MMP resistant peptide mutants have greater binding affinities to HLA‐A and HLA‐B when compared to MUC16, MMP nonresistant peptide mutants. Conclusion These results provide a potential, novel biomarker for lung cancer progression, in particular, protease resistant MUC16 peptides; and suggest a possible mechanism of immune escape entailing the reduction of mutant peptides available for HLA class I binding.